Abstract |
NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis and enhances anti- tumor immune responsiveness in tumor models. The addition of NOV-002 to chemotherapy has been shown to increase anti- tumor efficacy in animal models and some early phase oncology trials. We evaluated the clinical effects of NOV-002 in primary breast cancer, whether adding NOV-002 to standard preoperative chemotherapy increased pathologic complete response rates (pCR) at surgery, and determined whether NOV-002 mitigated hematologic toxicities of chemotherapy and whether levels of myeloid derived suppressor cells (MDSC) were predictive of response. Forty-one women with newly diagnosed stages II-IIIc HER-2 negative breast cancer received doxorubicin- cyclophosphamide followed by docetaxel (AC → T) every 3 weeks and concurrent daily NOV-002 injections. The trial was powered to detect a doubling of pCR rate from 16 to 32% with NOV-002 plus AC → T (α = 0.05, β = 80%). Weekly complete blood counts were obtained as well as circulating MDSC levels on day 1 of each cycle were quantified. Of 39 patients with 40 evaluable tumors, 15 achieved a pCR (38%), meeting the primary endpoint of the trial. Concurrent NOV-002 resulted in pCR rates for AC → T chemotherapy higher than previously reported. Patients with lower levels of circulating MDSCs at baseline and on the last cycle of chemotherapy had significantly higher probability of a pCR (P = 0.02). Further evaluation of NOV-002 in a randomized study is warranted.
|
Authors | A J Montero, C M Diaz-Montero, Y E Deutsch, J Hurley, L G Koniaris, T Rumboldt, S Yasir, M Jorda, E Garret-Mayer, E Avisar, J Slingerland, O Silva, C Welsh, K Schuhwerk, P Seo, M D Pegram, S Glück |
Journal | Breast cancer research and treatment
(Breast Cancer Res Treat)
Vol. 132
Issue 1
Pg. 215-23
(Feb 2012)
ISSN: 1573-7217 [Electronic] Netherlands |
PMID | 22138748
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antineoplastic Agents
- Drug Combinations
- NOV 002
- Taxoids
- Docetaxel
- Doxorubicin
- Cyclophosphamide
- ERBB2 protein, human
- Receptor, ErbB-2
- Cisplatin
- Glutathione Disulfide
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, pharmacology, therapeutic use)
- Breast Neoplasms
(drug therapy, metabolism, pathology, surgery)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Disease-Free Survival
- Docetaxel
- Doxorubicin
(administration & dosage)
- Drug Combinations
- Female
- Glutathione Disulfide
(administration & dosage)
- Humans
- Immunity, Cellular
(drug effects)
- Kaplan-Meier Estimate
- Mastectomy
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Invasiveness
- Neoplasm Staging
- Receptor, ErbB-2
(metabolism)
- Taxoids
(administration & dosage)
- Treatment Outcome
- Young Adult
|